Barrier Therapeutics Inactive 10-Q2008 Q1 Quarterly report

Filed: 9 May 08, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Good

New words: Additionally, Alfred, Altomari, Anne, attempt, backed, borrowing, broader, correlation, corroborated, cycle, downsizing, Dr, Food, Founder, FSP, global, hierarchy, housing, illiquidity, indirectly, joint, led, mandated, maximize, member, minimize, mortgage, nonfinancial, observable, outpaced, outsource, PDUFA, pervasive, predominantly, prepaid, President, professional, Quinnova, quoted, raw, Reilly, reoccur, represent, residential, respond, staffing, succeed, superficial, television, temporary, Tersi, toxicology, treat, unconsolidated, Unobservable, user, VanLent, Vice, warrant, workload

Removed: abroad, actively, acute, age, agent, allergic, antihistamine, April, arising, atopic, attribute, audit, called, Canadian, characterized, children, Constant, country, customer, deferral, Denavir, derecognition, disadvantage, distributor, diversify, doubtful, duration, earlier, eczema, entering, equipment, Europe, exclusivity, FIN, forward, fourth, harmed, Hatch, hedge, identified, impair, infected, inflammation, inflammatory, intercompany, interrupt, investigator, itch, larger, liquid, LLC, mild, moderate, move, mucosal, opening, point, positive, principle, procedure, promissory, promote, promotional, provision, pull, RAMBA, rash, receipt, relied, request, requiring, retained, satisfactory, scale, scaling, scalp, screening, sedation, strict, superior, supplement, sustained, tax, territory, theCandida, threshold, tinea, title, Toronto, treasury, trunk, unavailable, uncertainty, unfavorable, unreasonable, unrecognized, unsatisfactory, vaniqa, versicolor, Waxman, wholly, Zimycan

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Barrier Therapeutics similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Barrier Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dennis P. Reilly, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, based on my knowledge, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ DENNIS P. REILLY

Dennis P. Reilly

Chief Financial Officer

(Principal Financial Officer & Principal Accounting Officer)

May 9, 2008